UTMD · Utah Medical Products Inc

$70.99 -0.44 (-0.61%) At close · Aug 21

Market Cap

$227.39M

3.18M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin L. Cornwell	Chairman & CEO	$156,000	—	—	—	$289,800	$9,280	$455,080
Brian L. Koopman	Principal Financial Officer	$140,072	—	—	$9,887	$13,579	$4,255	$167,793

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin L. Cornwell	Chairman & CEO	$152,000	—	—	—	$349,650	$8,920	$510,570
Brian L. Koopman	Principal Financial Officer	$131,830	—	—	$12,543	$16,377	$4,569	$165,319

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin L. Cornwell	Chairman & CEO	$84,000	—	—	—	$360,150	$7,820	$451,970
Brian L. Koopman	Principal Financial Officer	$120,269	—	—	$25,341	$16,377	$4,412	$166,399

Executive changes

Person	Role	Change	Effective	Filed
Kevin Timken	Director	Appointed	2025-10-31	2025-11-04
Carrie Leigh	Director	Appointed	2024-11-01	2024-11-05

Key facts CIK 706698 CUSIP 917488108 13F (30d) 106 filings 104 filers Visit website Investor relations